ReviewTranslational neurodegeneration2017
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.
Review in Translational neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis.Neuropsychology review · 2023Pooled it
- Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2020Pooled it
- Multivariate radiomics models based onEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson disease.Annals of neurology · 2019Trial
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Translational neurodegeneration · 2026Review
- Artificial intelligence and multiomics integration for Parkinson's disease drug development.Molecules and cells · 2026Review
- The role of neuro-imaging in multiple system atrophy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- A case report: Neuroimaging in an atypical presentation of Parkinson's disease.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2026Article
- Functional MRI in Multiple System Atrophy: A Promising Biomarker for Clinical Applications.Neuropsychiatric disease and treatment · 2026Review
- Advances in ocular motor and pupil biomarkers for neurological disorders.Brain communications · 2026Review
- Review
- Development and in silico imaging trial evaluation of a deep-learning-based transmission-less attenuation compensation method for DaT SPECT.Medical physics · 2025Article
- Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Differentiating idiopathic Parkinson's disease from multiple system atrophy-P using brain MRI-based radiomics: a multicenter study.Therapeutic advances in neurological disorders · 2025Article
- Diagnostic Value of Carotid Intima-Media Thickness Combined with Periventricular White Matter Hyperintensities for Mild Cognitive Impairment in Parkinson's Disease.Neuropsychiatric disease and treatment · 2025Article
- Longitudinal decline in DAT binding in Parkinson's disease: connections with sleep disturbances.BMC medicine · 2024Article
- First-in-human study of D6-[EJNMMI radiopharmacy and chemistry · 2024Article
- Evaluation of damage discrimination in dopaminergic neurons using dopamine transporter PET tracer [EJNMMI research · 2024Article
- Parkinson's Disease Recognition Using Decorrelated Convolutional Neural Networks: Addressing Imbalance and Scanner Bias in rs-fMRI Data.Biosensors · 2024Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two centuries ago in 1817, James Parkinson provided the first medical description of Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to include the atypical parkinsonian variants (also termed, Parkinson-plus syndromes). Today, Parkinson's disease represents the second most common neurodegenerative disorder with an estimated global prevalence of over 10 million. Conversely, atypical parkinsonian syndromes encompass a group of relatively heterogeneous disorders that may share some clinical features with Parkinson's disease, but are uncommon distinct clinicopathological diseases. Decades of scientific advancements have vastly improved our understanding of these disorders, including improvements in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.